Retevmo: Indication and Usage



Retevmo (selpercatinib) is a kinase inhibitor recommended by healthcare professionals to treat patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and locally advanced or solid metastatic tumors with a RET gene fusion. 

Indications and Usage

RET Fusion-Positive Non-Small Cell Lung Cancer

Healthcare professionals recommend Selpercatinib for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 

Non-small cell lung cancer is one of the common types of lung cancer. With this disease, cancer cells begin in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer — but it often spreads to other parts of your body by the time it's diagnosed. 

RET-Mutant Medullary Thyroid Cancer 

The medicine Retevmo (Selpercatinib) is used by healthcare providers to treat RET-Mutant Medullary Thyroid Cancer. 

Medullary thyroid cancer (MTC) is cancer that forms in the thyroid. The thyroid is a gland found in the front of your neck, just beneath Adam's apple, and it is responsible for sending out hormones to the rest of the body. The inside of the thyroid is known as the medulla.

RET Fusion-Positive Thyroid Cancer

Healthcare professionals recommend Retevmo 40 mg and 80 mg for treating adult and pediatric patients 12 years of age with advanced or metastatic thyroid cancer with a RET gene fusion. 

Metastatic thyroid cancer, also referred to as stage 4 thyroid cancer, has spread from the thyroid gland to other areas of the body. Thyroid cancer is an uncontrollable growth of cells that begins in the thyroid. The thyroid gland is butterfly-shaped and found at the base of the neck, just below Adam's apple.

Other RET Fusion-Positive Solid Tumors

Retevmo (Selpercatinib) is recommended for treating locally advanced or metastatic solid tumors with a RET gene fusion that has progressed on or following prior systemic therapy or who have no satisfactory substitute treatment options in adult patients.

An abnormal mass of tissue that usually does not have cysts or liquid areas. Solid tumors could not be cancerous or cancerous. 

Recommended Dosage

Healthcare professionals would select patients for treatment with Retevmo based on the presence of a RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma. 

One can take Selpercatinib with or without food unless coadministered with a proton pump inhibitor (PPI).

The recommended Retevmo dosage based on body weight is:

  •  Less than 50 kg: 120 mg
  •  50 kg or greater: 160 mg

One should take Retevmo orally twice daily (approx. every 12 hours) until disease progression or unacceptable toxicity. 

Note: Retevmo dosage depends upon the type of disease and the patient's health history.

Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Lenvatinib Medication Guide

Lenvatinib is recommended for treating patients with locally recurrent, progressive, metastatic, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), together with everolimus for advanced renal cell carcinoma and for hepatocellular carcinoma.  Here are a few important points for patients before taking Lenvatinib:- Female patients who are able to become pregnant must use an effective method of birth control while on the treatment with lenvatinib and for at least 2 weeks after its last dose. Discuss with your doctor about the birth control methods you can use during this time. Lenvatinib is taken at the same time each and every day. If a patient misses any dose, and it cannot be consumed within 12 hours, then that dose must be skipped and the next dose should be consumed at the usual time of administration. The recommended dose is lenvatinib 24 mg (two lenvatinib 10 mg capsules and one lenvatinib 4 mg capsule) orally, taken once in a day, either with or wit
Read more

Difference Between Multiple Myeloma And Leukemia

Image
What is multiple myeloma:  This is also known as plasma cell myeloma or Kahler's disease. It is a cancer in plasma cells that typically produce antibodies. When there is only one tumor present it is called as plasmacytoma and when more than one then called as multiple myeloma. The main cause of myeloma is unknown but the major risk factors are obesity,  inheritance chemicals, radiation, etc. With the effect of cancer, there is an abnormality in plasma cells that produces abnormal antibodies that can cause kidney problems. At the initial stage, there is no sign and symptoms but with the advancement of time bone pain, bleeding, anemia and frequent infections are the common symptoms. Multiple myeloma is diagnosed with the help of blood or urine tests or bone marrow biopsy. And the medication of multiple myeloma includes: Chemotherapy- There are several drugs that are used in the treatment of multiple myeloma such as doxorubicin, etoposide, cisplatin, cyclophosphamide, e
Read more